Hypothermia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hypothermia is an emerging landscape with 20 programs across 11 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Neurim Pharmaceuticals Ltd., Nobilis Therapeutics Inc.. 4 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
Neurim Pharmaceuticals Ltd.
1 program
Nobilis Therapeutics Inc.
1 program
Immunex
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Fresenius Kabi Oncology Ltd.
2 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
95%
Small molecule
20 of 21 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.
Analysis
Trial Status
18
clinical trials
Clinical Trials
Trial Activity
18 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)